News | News By Subject | News by Disease News By Date | Search News

Melanoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Array BioPharma (ARRY) Has a Potential Blockbuster Melanoma Drug On Its Hands     2/13/2017
Two Deaths Linked to Bristol-Myers Squibb (BMY)'s Yervoy-Opdivo Combo     11/3/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine     7/7/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues     6/17/2016
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma     5/11/2016
Investors Unhappy as Caladrius Biosciences (CLBS) Kills Phase III Oncology Program, Lays Off 40 in SoCal     1/8/2016
Array BioPharma (ARRY) Surges as Binimetinib Meets Goals in Late-Stage Study     12/16/2015
FDA Grants Full U.S. Approval for Novartis AG (NVS)' Targeted Skin Cancer Combo     11/23/2015
FDA Approves Daiichi Sankyo, Plexxikon's Cobimetinib In Combination With Zelboraf for Advanced Melanoma Patients     11/11/2015
FDA Green Lights Genentech (RHHBY)'s Vemurafenib/Cobimetinib Combo for Melanoma     11/10/2015
Investors Elated as Amgen (AMGN) Wins FDA Approval for First-of-Its-Kind Cancer Killing Virus Drug     10/30/2015
Investors Hold Their Breath as Amgen (AMGN) Inches Toward U.S. Approval for Its New Cancer Immunotherapy T-Vec     10/26/2015
Exelixis (EXEL), Genentech (RHHBY)'s Cobimetinib Succeeds in Pivotal Phase III Trial     10/8/2015
FDA Green Lights Bristol-Myers Squibb (BMY)'s Drug Combo for Metastatic Melanoma     10/2/2015
Joining the Anti-PD-L1 Cancer Drug Market, Syndax Inks Deal With Genentech (RHHBY), Closes on $80 Million Series C Round     8/27/2015

News from Around the Web
New Microscopic Technique Could Help Detect, Diagnose Metastatic Melanomas, Royal Society Of Chemistry Reveals     5/5/2017
New Technique Spots Pheomelanin In Pale Patients At Risk Of Dangerous Melanoma, Massachusetts General Hospital Reveals     3/8/2017
Genetic Causes Of Higher Melanoma Risk In Men Discovered, Universitat Jaume I de Castellón Reveals     7/22/2016
Microneedle Patch Delivers Localized Cancer Immunotherapy To Melanoma, North Carolina State University Study     3/25/2016
Pharma's Big New Cancer Drug May Be An Old Red Dye     2/26/2016
Vitamin B3 Derivative Cuts Risk Of New Skin Cancers, University of Sydney Study     10/22/2015
Could Laser Skin Test Replace Biopsy For Melanoma? Lancaster University Study     8/24/2015
Coffee Lowers Deadly Skin Cancer Risk, Yale School Of Public Health Study     1/22/2015
Sunscreens Do Not Fully Protect Against Skin Cancer, University Miguel Hernández Study     7/16/2014
Viagra Poses Cancer Risk For Men, JAMA Reveals     6/6/2014
Pine Bark Substance Could Treat Melanoma, Penn State Hershey Melanoma Center Study     5/22/2014
Link Between Viagra And Melanoma Discovered, JAMA Reveals     4/11/2014
Melanoma In Families Linked To Mutations In One Gene, University of Leeds Study     4/3/2014
Sleep Apnea Severity Predicts Aggressiveness of Melanoma, Hospital de Valme Study     9/9/2013
Gene Mutation Immortalizes Malignant Melanoma, University Duisburg-Essen Study     1/28/2013

Press Releases
BerGenBio AS Announces Start Of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 In Combination With Current Therapies In Melanoma     5/22/2017
NYU Langone Medical Center Release: Erectile Dysfunction Medicines Do Not Cause Melanoma, Analysis Of Large Studies Finds     5/19/2017
Syndax Announces Results From Phase II ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA (Pembrolizumab) For The Treatment Of Advanced Melanoma     5/18/2017
Castle Biosciences Release: Study Demonstrates Significant And Risk-Appropriate Clinical Impact Of DecisionDx-Melanoma Test Results On Patient Management Decisions     5/15/2017
Array BioPharma (ARRY) Shows Off Phase III Melanoma Data, Stock Jumps     5/11/2017
Targovax Recruits First Patient Into First ONCOS-102 /Checkpoint Inhibitor Melanoma Study     5/10/2017
Bristol-Myers Squibb (BMY) And Calithera Biosciences (CALA) Expand Collaboration Evaluating Opdivo (Nivolumab) In Combination With CB-839 Into Non-Small Cell Lung Cancer And Melanoma     5/10/2017
OncoSec Medical Announces Clinical Collaboration With Merck & Co. (MRK) To Evaluate Combination Of Immunopulse IL-12 And KEYTRUDA (Pembrolizumab) For Metastatic Melanoma     5/10/2017
Castle Biosciences’ Decisiondx-Melanoma Test Accurately Predicts Metastatic Risk In Patients With Head And Neck Melanoma     5/1/2017
Prima Biomed (PRR.AX) Receives Approval For Third Cohort Of Phase I Melanoma Trial     4/19/2017
Idera Pharma (IDRA) Advances Investigational Treatment—Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma     4/11/2017
Pivotal Study Results For Myriad Genetics (MYGN)’s myPATH Melanoma Test Highlighted In Two Additional Scientific Publications     4/5/2017
NewLink Genetics (NLNK) Release: Interim Phase II Data Demonstrate Robust Response Rate With Indoximod In Combination With Keytruda® (Pembrolizumab) For Patients With Advanced Melanoma At AACR Plenary     4/4/2017
Investors Sigh With Relief As Bristol-Myers Squibb (BMY)'s Immunotherapy Combo Extends Survival In Melanoma Patients     4/3/2017
Aura Biosciences Announces Initiation Of Phase Ib Clinical Trial And Receipt Of FDA Fast Track Designation For AU-011 For The Treatment Of Primary Ocular Melanoma     3/30/2017

//-->